EnPro acquires the Aseptic Group to expand fluid handling portfolio
Category: #business  By Nikita Chaurasia  Date: 2019-07-04
  • share
  • Twitter
  • Facebook
  • LinkedIn

EnPro acquires the Aseptic Group to expand fluid handling portfolio

Acquisition of Aseptic Group represents the ongoing commitment towards investing in the biopharmaceutical and pharmaceutical industries

EnPro Industries, a leading manufacturer of engineered industrial products, has reportedly acquired The Aseptic Group, a privately-owned company which supplies, manufactures, and designs aseptic fluid transfer products for the biopharmaceutical and pharmaceutical industries.

Apparently, the Aseptic Group will become part of Garlock Family of Companies owned by EnPro, which is a leading worldwide supplier of high-performance fluid handling and sealing products to process industries. The deal was completed in the form of cash transaction.

According to President of Garlock, Mike Faulkner, focus of The Aseptic Group is highly aligned with strategic market vision of Garlock. With world-class manufacturing, expert product design knowledge and supply chain integrity, the platform of Aseptic Group is extremely leverageable as the company continues to build global capabilities, he remarked.

This addition will supposedly enable Garlock to further expand the product offerings and deliver value-added solutions to further reinforce the customer value in highly regulated and demanding industries, Faulkner said.

Sources close to the matter informed that The Aseptic Group supplies fluid path components of high purity and has been aiding some of the world’s greatest pharmaceutical companies for more than 20 years. It’s headquartered in Limonest, France. The company is at the leading edge of developing products and capabilities to bolster the new manufacturing techniques presently being adopted to create future generation biopharmaceutical drugs.

The high level of operational excellence, strict documentation and product quality anticipated by this developing industry requires profound understanding, investment, and expertise as compared to traditional pharmaceutical manufacturing, sources commented.

The acquisition of Aseptic Group represents the ongoing commitment towards investing in the biopharmaceutical and pharmaceutical industries that form a vital part of the growth plan for Garlock. The company is looking forward to the benefits this business combination will bring to the customers and collective team, President and Chief Executive Officer of EnPro Industries, Steve Macadam mentioned.

Source Credit: https://www.enproindustries.com/press-release/financial/enpro-industries-announces-acquisition-aseptic-group

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

Japan’s SoftBank amid plans to invest in venture capital funds
Japan’s SoftBank amid plans to invest in venture capital funds
By Nikita Chaurasia

The conglomerate plans to mark its presence in Latin America by investing in venture capital funds, with a strategy to deploy nearly $500 million in five to 10 funds. SoftBank Group Corp., a multinational conglomerate based out of Tokyo, reportedly ...

TG Manufacturing acquires contract manufacturing firm TurnKey
TG Manufacturing acquires contract manufacturing firm TurnKey
By Nikita Chaurasia

TurnKey presently supplies a varied group of consumers in the industrial laboratory, defense and gaming industries among others. Using TGM’s advanced manufacturing technology, quality systems and global network and combining them with TurnKe...

Oxurion concludes enrollment of patients for THR-687 Phase 1 trial
Oxurion concludes enrollment of patients for THR-687 Phase 1 trial
By Nikita Chaurasia

12 patients with DME have enrolled into the study.   The results for the Phase 1 trial will be out by the end of 2019. Oxurion NV, a biopharmaceutical firm involved in the development of innovative treatments to preserve vision of diabetic...